Physician profile
Michael Theodore Peterson
NPI 1194768606
$1,174.58
in general payments reported to CMS, 2019-2025
15 companies · $46.78 in 2025
The $46.78 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $133 · 2021: $11.88 · 2022: $30.51 · 2025: $46.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $165.20 | 2019-2020 | |
| Lilly USA, LLC | $161.90 | 2019 | |
| Janssen Pharmaceuticals, INC | $154.90 | 2019-2020 | |
| Novo Nordisk INC | $136.40 | 2019-2020 | |
| Amarin Pharma, INC. | $113.85 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $81.19 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $79.56 | 2019 | |
| Amgen INC. | $70.62 | 2019 | |
| Merck Sharp & Dohme LLC | $66.13 | 2019-2020 | |
| Esperion Therapeutics, INC. | $46.78 | 2025 | Nexletol |
| Glaxosmithkline, LLC. | $30.51 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.12 | 2019 | |
| Radius Health, INC. | $13.57 | 2020 | |
| Allergan, INC. | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.